Advancing Scientific Research Through Open Access

Thyroid carcinoma is the most common endocrine malignancy, accounting for a significant proportion of cancer diagnoses worldwide. The incidence of thyroid cancer has been rising steadily over the past few decades, largely due to improved diagnos tic imaging techniques such as high-resolution ultrasonography. Despite advancements in imaging and cytological evaluation, accurate risk stratification remains a clinical challenge, particularly in cases categorized as indeterminate thyroid nodules [2].

Dental X-rays play a crucial role in contemporary dental practice by facilitating precise diagnosis, treatment strategies, and fol low-up of oral health issues [1]. Visualizing tooth roots, bone structures, and nearby tissues is crucial for thorough oral health evaluations and X-rays assist in performing intricate procedures like root canals and dental implants. Moreover, dental X-rays serve as a crucial component in monitoring the progression of dental conditions and evaluating the success of treatments over time. Despite their clinical signi cance, patient anxiety surrounding dental X-rays remains a prevalent issue in dental practices worldwide.

The global leather industry is undergoing a profound transformation, driven by the relentless advancement of digital technolo gies. From automated design and precision manufacturing to data-driven supply chain management and hyper-targeted mar keting, digitalization is reshaping competitive landscapes worldwide

About 1 to 2% of all exocrine pancreatic neoplasms are Solid pseudopapillary neoplasms (SPNs) with strong predilection to girls and young women usually in their 2nd or 3rd decade of life [1]. SPNs can occasionally display aggressive behavior, local in vasion or distant metastasis (10-15% of cases).

For overall context, some key pharma and biotech companies’ activities in biotechnology for 2025 are provided as follows; 192 companies marketed 783 biotech products worldwide. The listed products are approved in the United States and Europe pri marily for the largest markets, and also include Australia, Canada, and Japan. Growth rate for biotech product approvals in United States is provided subsequently in 5-year intervals. USA approvals started slowly for 1980-1994, picked up in rate for 1995-2009, and grew quite rapidly 2010-2025: 5 in pre-1980 years; followed by + 5 in 1980-1984; + 19 in 1985-1989; + 24 in 1990-1994; + 56 in 1995-1999; + 66 in 2000-2004; + 48 in 2005-2009; + 81 in 2010-2014; + 158 in 2015-2019; + 207 in 2020-2024; + 73 in 2025-6/2026 [1&1/2 years]. A total of 742 product approvals occurred in USA, of which 81 have been dis continued because mostly being superseded by a superior product. An additional 123 biotech products have been approved by the European Union and Japan. Their worldwide cost was calculated to be $662 billion in 2025. The specific indications for th ese biotech products number over 750 addressing all therapeutic areas, often achieving substantial disease control, which could not be accomplished without them.

PWS is increasingly recognized as a “functional vital sign” and is associated with future health outcomes, including hospitaliza tion, cognitive decline, falls, and mortality [1-5]. A PWS > 1.0 m/s is generally associated with good health and functional inde pendence, whereas walking speeds < 0.6 m/s may represent a clinical “yellow ” for increased health risks and functional dec line [1-3]. Furthermore, a change of approximately 0.1 m/s is considered minimally detectable or clinically meaningful improve ment in walking performance [3-5]. However, walking safety and y may be d by multiple factors including age, sex, medical comorbidities, musculoskeletal impairment, and orthopedic surgical procedures [5-7].